Clinical trials: Tenofovir Alafenamide Fumarate
Tenofovir, Tenofovir Alafenamide Fumarate
Tenofovir Exposures in Advanced Kidney Disease Study
Phamacokinetic study to evaluate tenofovir, emtricitabine and tenofovir alafenamide exposures in people with HIV who have chronic kidney disease stage 4 (estimated glomerular filtration rate [eGFR] 15-29 mL/min/1.73m2) or stage 3…
- Conditions
- Tenofovir, Tenofovir Alafenamide Fumarate, Chronic Kidney Diease, Kidney Failure
- Trial name
- TEAK (NCT07812571)
- Testing
- Plasma sampling for tenofovir and emtricitabine, Descovy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- King's College Hospital NHS Trust
Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
- Trial name
- NCT05853718
- Testing
- Tenofovir Alafenamide Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Hangzhou
Chronic Hepatitis B, Mother-to-Child Transmission
Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B
To investigate the safety and efficacy of tenofovir alafenamide (orally 25 mg per day) treated in inactive chronic hepatitis B virus (HBV)-infected pregnant women with high viral load from the late pregnancy until the delivery…
- Conditions
- Chronic Hepatitis B, Mother-to-Child Transmission, Safety, Efficacy
- Trial name
- TAF-PPT (NCT04850950)
- Testing
- Tenofovir Alafenamide fumarate 25mg Oral Tablet
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University